

November 17-20 2024, Barcelona, Spain

Budget Impact Analysis of Paliperidone Palmitate in Chronic Schizophrenia in the Mental Health Secretariat-Egyptian Ministry of Health

Elsisi G¹, Amin M², Abdel Hamid M³, Abdel Maksoud M^{2,4}, Antar A⁵, Abdelmalak M⁵, Ragab A⁵, Dawood H⁵
¹The American University in Cairo, Egypt, ²Mental Health & Addiction treatment, MoH, Cairo, Egypt, ³GSMHAT, MoH, Alexandria, Egypt, ⁴Ain Shams University, Cairo, Egypt, ⁵Johnson & Johnson, Cairo, Egypt

Introduction

Our aim is to evaluate the budget impact of long-acting injection paliperidone palmitate (LAI-PP) in chronic schizophrenia versus daily oral antipsychotics from societal perspective over a time horizon of 1 year.

Methodology

A budget impact model was performed to compare LAI-PP to antipsychotics (risperidone, olanzapine and aripiprazole) in chronic schizophrenia patients. Our study included therapies used during relapse and hospitalization, validated by the local clinical practice. The clinical parameters for hospitalization, and adherence of all treatments were extracted from PRIDE trial. Direct medical costs and indirect costs were measured in our study. The unit cost of drug acquisition for all medications were extracted from the ministry of health sector, and multiplied by the utilization of each drug. One-way sensitivity analyses were conducted to assess the model uncertainty.

Expert Panel Survey Questions

Health Insurance Sector Target Population

Related Questions:

1. What is the estimated prevalence of schizophrenia patients in Egypt? What is the estimate for schizophrenia?
2. Of these, what is the percentage of patients that are eligible to receive paliperidone palmitate monthly schedule? (treated and diagnosed)

Therapeutic-Lines Related Questions:


1. What is the currently used therapeutic schedule within local settings for the treatment of schizophrenia patients ? any monitoring tests? What are their market shares?
Is there use of any generics?
2. What are the most common AEs that occur with these treatment schedules within the Egyptian patients? And how is these AEs managed?
3. What is the percent of adherence on all schedules?

Relapse Related Questions:

1. What do Schizophrenia patients receive after relapse on these treatment schedules (paliperidone palmitate 1-monthly and its comparators), specify the schedule in details?
- 2- Are any physician visits, monitoring required to those patients? Outpatient costs?


Management Related Questions:

1. Are there any concomitant treatments or pre-medications that given with the treatment schedules? If present; please provide their schedules (doses and durations)?
2. What are the resources used in the following health states?
 - in stable disease,
 - experiencing relapse,
 - experiencing acute (prolactin-related disorders and extrapyramidal symptoms) or permanent (weight gain and diabetes) adverse events.



Results

The target population in our model was estimated to be 30 patients.



Total Budget Saving = **EGP 306,708**

Savings per patient per year = **EGP 5,112**

Hospitalizations avoided per year = **4**

Conclusion:

The lower hospitalization rates of LAI-PP are offset the increase in upfront costs due to the cost savings from societal perspective compared to the standard of care in chronic schizophrenia. Policy makers should consider this approach to improve patient outcomes and budget sustainability.

* Address correspondence to:

Gihan Hamdy El-sisi, MSc, PhD
Managing Director, HTA Office, Middle East and North Africa
Health Science Policy Council Advisor, ISPOR
Assistant Professor_Health Economics, American University in Cairo

Al Quoz 1, P.O. Box No. 118962, Dubai, United Arab Emirates
Tel.: +202 - 2275 5016 Mob: (+20)1227366018

Acknowledgment:

Fady Abdelmalek, PharmB, HEOR Specialist, HTA Office, Middle East and North Africa.
Tel.: +202 - 2275 5016